快报！京剧经典再现荧幕：《四郎探母》《红楼二尤》等四部电影全国上映

京剧经典再现荧幕：《四郎探母》《红楼二尤》等四部电影全国上映

北京 - 2023年4月25日，由“京剧电影工程”推出的四部京剧电影《四郎探母》《红楼二尤》《群英会·借东风》《文姬归汉》在全国范围上映。这标志着“京剧电影工程”第二批重点影片正式与观众见面。

《四郎探母》取材于元代戏曲剧本《孝义村》，讲述了杨延辉为母千里寻访的故事，是京剧中最为经典的剧目之一。此次电影版《四郎探母》由著名京剧表演艺术家张建峰、窦晓璇主演，在保留传统戏曲表演特色的同时，也运用了现代电影技术，为观众呈现出更加生动感人的视觉效果。

《红楼二尤》改编自中国古典名著《红楼梦》，以黛玉、宝钗二人の命运为主线，展现了封建社会下女性的悲剧人生。电影版《红楼二尤》由著名京剧表演艺术家罗戎征、唐禾香主演，在服装、道具、场景等方面都进行了精心考究，力求还原红楼世界的真实风貌。

《群英会·借东风》取材于三国演义，讲述了诸葛亮舌战群儒、智借东风的故事。电影版《群英会·借东风》由著名京剧表演艺术家叶少兰、朱强主演，在展现人物性格和戏剧矛盾方面都颇具亮点。

《文姬归汉》讲述了东汉女诗人蔡文姬被匈奴掳掠后，历经磨难最终回归汉朝的故事。电影版《文姬归汉》由著名京剧表演艺术家迟小秋主演，将蔡文姬的巾帼不让须眉的英雄气概演绎得淋漓尽致。

“京剧电影工程”是由国家新闻出版广电总局、中国电影股份有限公司、中国京剧艺术基金会等单位联合推出的重点文化工程，旨在通过电影手段，传承和弘扬京剧艺术。自2011年启动以来，该工程已陆续推出了多部优秀京剧电影，为观众带来了全新的观戏体验。

此次上映的四部京剧电影，是“京剧电影工程”的又一次成果。这些电影不仅在制作上精益求精，而且在阵容上也十分强大，汇集了众多京剧名家名角。相信这些电影的上映，将有利于推动京剧艺术的普及和推广，让更多观众感受国粹的魅力。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.